Advertisement

Journal of Computer-Aided Molecular Design

, Volume 23, Issue 4, pp 195–198 | Cite as

ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI)

  • Wendy A. Warr
Warr's Piece

John Overington holds a first degree in chemistry, and studied for his PhD on comparative protein modeling, drug design, and sequence-structure relationships with Sir Tom Blundell FRS, at Birkbeck College, London. After a postdoctoral fellowship with the Imperial Cancer Research Fund, London, he joined Pfizer Central Research in the UK and eventually became manager of the Molecular Informatics, Structure and Design Department, where he was responsible for cheminformatics, structural biology, target analysis, and molecular modeling. He joined Inpharmatica in 2000; Inpharmatica was acquired by Galapagos NV in December 2006. There he was Senior Director, Discovery Informatics of the Galapagos subsidiary BioFocus DPI. In October 2008 he was appointed Team Leader, Chemogenomics at the European Molecular Biology Laboratory (EMBL), working at the European Bioinformatics Institute (EMBL-EBI) in Hinxton, UK. His ChEMBL group’s research focuses on mapping the interactions and functional effects...

Keywords

Imperial Cancer Research Fund Discovery Informatics Pfizer Central Research Structure Analysis Tool German Chemical Society 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    ChEMBL http://www.ebi.ac.uk/chembl/. Accessed November 2008
  2. 2.
    Overington JP, Al-Lazikani B, Hopkins AL (2006)) Nat Rev Drug Discov 5:993. doi: 10.1038/nrd2199 CrossRefGoogle Scholar
  3. 3.
    Agüero F, Al-Lazikani B, Aslett M, Berriman M, Buckner FS, Campbell RK et al (2008) Nat Rev Drug Discov 7:900. doi: 10.1038/nrd2684 CrossRefGoogle Scholar
  4. 4.
    ChEBI http://www.ebi.ac.uk/chebi/. Accessed November 2008
  5. 5.
    Steinbeck C, Han Y, Kuhn S, Horlacher O, Luttmann E, Willighagen E (2003) J Chem Inf Comput Sci 43:493. doi: 10.1021/ci025584y Google Scholar
  6. 6.
    Steinbeck C, Hoppe C, Kuhn S, Floris M, Guha R, Willighagen EL (2006) Curr Pharm Des 12:2111. doi: 10.2174/138161206777585274 CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2009

Authors and Affiliations

  1. 1.Wendy Warr & AssociatesCheshireUK

Personalised recommendations